|
|
|
22 Apr 2008 |
VIVUS Completes Enrollment in the Third Phase 3 CONQUER (OB-303) Trial
|
|
22 Apr 2008 |
Orexigen(R) Therapeutics Announces Completion of Enrollment in Second of Four Phase III Clinical Trials for Contrave(R)
|
|
22 Apr 2008 |
Eurand Announces EUR-1008 (Zentase) Eligibility for European Centralized Review
|
|
21 Apr 2008 |
Raptor Pharmaceuticals initiates phase IIa clinical study for Convivia
|
|
21 Apr 2008 |
Savient Provides Update On Puricase(R) (pegloticase) Biologics License Application
|
|
21 Apr 2008 |
Recordati: Orphan Europe filed Carbaglu NDA with the FDA in the U.S.
|
|
21 Apr 2008 |
Genzyme Provides Update on Myozyme(R) Manufacturing
|
|
21 Apr 2008 |
Genzyme Provides Update on Myozyme(R) Manufacturing
|
|
18 Apr 2008 |
Lipid Sciences Presents HDL Mimetic Peptide Data at Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference
|
|
17 Apr 2008 |
Sirtris Announces SRT501 Lowers Glucose in Twice-Daily Dosing Clinical Trial; Study Suggests Dose Response for Proprietary Formulation of Resveratrol in Type 2 Diabetics
|
|
16 Apr 2008 |
Aldagen Announces Initiation of ALD-101 Phase III Trial for Improving Cord Blood Transplants in Pediatric Patients With Inherited Metabolic Diseases
|
|
16 Apr 2008 |
Zelos Therapeutics and Aegis Therapeutics Announce Collaboration for Intranasal Delivery of Zelos’ ZT-031
|
|
16 Apr 2008 |
Positive Results in First Clinical Study with Anti Diabetes Compound KB3305
|
|
15 Apr 2008 |
Kythera Biopharmaceuticals Announces Second Phase II Clinical Trial With Adipolytic Agent for Reduction of Submental Fat
|
|
15 Apr 2008 |
Lexicon Presents Clinical Data for LX6171, a Drug Candidate for Cognitive Disorders
|
|
14 Apr 2008 |
AtheroGenics Announces Encouraging Interim Results From Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes
|
|
14 Apr 2008 |
Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
|
|
11 Apr 2008 |
Study shows once-yearly Aclasta(R) better than risedronate at increasing bone mass in patients with osteoporosis caused by glucocorticoids
|
|
09 Apr 2008 |
Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
|
|
09 Apr 2008 |
Pfizer Statement on Exubera Labeling Update in the United States
|
|
09 Apr 2008 |
Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
|
|
08 Apr 2008 |
Bristol-Myers Squibb Selects Isis Drug Targeting PCSK9 as Development Candidate for Prevention and Treatment of Cardiovascular Disease
|
|
08 Apr 2008 |
Rigel's R788 Shows Preclinical Activity in Type 1 Diabetes Model
|
|
04 Apr 2008 |
Takeda Wins Definitive Decision in Patent Infringement Litigation on Appeal against an ANDA Filer for Generic ACTOS(R)
|
|
04 Apr 2008 |
FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis
|
|
03 Apr 2008 |
Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
|
|
02 Apr 2008 |
Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis
|
|
02 Apr 2008 |
Pivotal Phase 3 Data Show Denosumab Increased Bone Density at Multiple Skeletal Sites in Early and Later Stage Postmenopausal Women
|
|
01 Apr 2008 |
Update on ACHIEVE: A Study of Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE(TM))
|
|
31 Mar 2008 |
Naglazyme Approved by Japanese Ministry of Health
|
|
31 Mar 2008 |
Abbott's Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
|
|
31 Mar 2008 |
Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss
|
|
31 Mar 2008 |
Patients Treated with Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE(TM)) Reported Significantly Less Flushing Than Patients Treated with Niaspan(TM) in Phase III Study
|
|
28 Mar 2008 |
Discontinuation of Development of TAK-475, A Compound for Treatment of Hypercholesterolemia
|
|
27 Mar 2008 |
Karo Bio strengthens eprotirome Phase II program with additional clinical study
|
|
27 Mar 2008 |
Genfit shows encouraging results in GFT505 first clinical trial of efficacy
|
|
27 Mar 2008 |
VIVUS Completes Enrollment in Phase 3 EQUIP (OB-302) Trial
|
|
26 Mar 2008 |
SemBioSys initiates toxicology study for safflower-produced insulin
|
|
26 Mar 2008 |
Metabolex Initiates Phase 1 Trial of MBX-2982
|
|
25 Mar 2008 |
Elixir Announces Completion of Enrollment in Pivotal Phase III Clinical Trial for New Diabetes Drug
|
|
19 Mar 2008 |
Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes
|
|
18 Mar 2008 |
Hollis-Eden Pharmaceuticals Reports Positive Preliminary Data from Ongoing Phase I/II Clinical Trial with TRIOLEX(TM) in Obese Insulin Resistant Subjects
|
|
17 Mar 2008 |
Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone
|
|
14 Mar 2008 |
Diamyd Gets Authorization to Begin Phase III Study in the US
|
|
13 Mar 2008 |
Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
|
|
13 Mar 2008 |
Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
|
|
13 Mar 2008 |
Neurochem Inc. Moves Eprodisate Drug Development Program Forward for Amyloid A Amyloidosis
|
|
12 Mar 2008 |
Unigene Successfully Completes Phase I/II Clinical Study for Oral Calcitonin
|
|
11 Mar 2008 |
FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
|
|
07 Mar 2008 |
Alkermes Provides Update on Inhaled Insulin Program
|
| |
|
Results 201 - 250 of 1041 |
